tetano
Editor, Senior Moderator
J Med Virol
. 2022 Aug 24.
doi: 10.1002/jmv.28085. Online ahead of print.
Clinical characteristics and outcomes of patients with COVID-19 and psoriasis
Yu Meng[SUP] 1 2 [/SUP], Furong Zeng[SUP] 1 2 3 [/SUP], Huiyan Sun[SUP] 1 2 [/SUP], Yayun Li[SUP] 1 2 [/SUP], Xiang Chen[SUP] 1 2 [/SUP], Guangtong Deng[SUP] 1 2 [/SUP]
Affiliations
Abstract
Objectives: To summarize the clinical characteristics and explore the role of treatment types in outcomes among psoriasis patients with Coronavirus Disease 2019 (COVID-19).
Methods: The principal summary measures used were pooled prevalence and risk ratio (RR) with 95% confidential interval (CI). R statistic software was used for all the analysis.
Results: A total of 19 studies including 4073 psoriasis patients with COVID-19 were eligible for the meta-analysis. The overall hospitalization rate is about 20.2% (95% CI, 12.7% - 28.7%), and changed to be 18.0 (95% CI, 9.9% - 27.6%) or 14.1 (95% CI, 5.9% - 24.6%) after systemic or biologic treatment. Moreover, the overall fatality rate is 1.5% (95% CI, 0.4% - 3.0%), and turned to be 0.7 (95% CI, 0 - 2.0%) or 0.5 (95% CI, 0 - 2.2%) after systemic or biologic therapy. Notably, a lower hospitalization risk ratio was found in patients receiving biologic therapy than those receiving other treatments (RR = 0.62, 95%CI, 0.42-0.94). The results were consistent after sensitivity analysis and trim-and-fill analysis.
Conclusions: Systemic, especially biologic therapy could lessen the clinical severity in psoriasis patients with COVID-19. Our finding will help to guide current recommendations and provide a reference for clinical decision-making. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Clinical characteristics; Outcomes; Psoriasis; Systemic or biologic therapy.
. 2022 Aug 24.
doi: 10.1002/jmv.28085. Online ahead of print.
Clinical characteristics and outcomes of patients with COVID-19 and psoriasis
Yu Meng[SUP] 1 2 [/SUP], Furong Zeng[SUP] 1 2 3 [/SUP], Huiyan Sun[SUP] 1 2 [/SUP], Yayun Li[SUP] 1 2 [/SUP], Xiang Chen[SUP] 1 2 [/SUP], Guangtong Deng[SUP] 1 2 [/SUP]
Affiliations
- PMID: 36000295
- DOI: 10.1002/jmv.28085
Abstract
Objectives: To summarize the clinical characteristics and explore the role of treatment types in outcomes among psoriasis patients with Coronavirus Disease 2019 (COVID-19).
Methods: The principal summary measures used were pooled prevalence and risk ratio (RR) with 95% confidential interval (CI). R statistic software was used for all the analysis.
Results: A total of 19 studies including 4073 psoriasis patients with COVID-19 were eligible for the meta-analysis. The overall hospitalization rate is about 20.2% (95% CI, 12.7% - 28.7%), and changed to be 18.0 (95% CI, 9.9% - 27.6%) or 14.1 (95% CI, 5.9% - 24.6%) after systemic or biologic treatment. Moreover, the overall fatality rate is 1.5% (95% CI, 0.4% - 3.0%), and turned to be 0.7 (95% CI, 0 - 2.0%) or 0.5 (95% CI, 0 - 2.2%) after systemic or biologic therapy. Notably, a lower hospitalization risk ratio was found in patients receiving biologic therapy than those receiving other treatments (RR = 0.62, 95%CI, 0.42-0.94). The results were consistent after sensitivity analysis and trim-and-fill analysis.
Conclusions: Systemic, especially biologic therapy could lessen the clinical severity in psoriasis patients with COVID-19. Our finding will help to guide current recommendations and provide a reference for clinical decision-making. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Clinical characteristics; Outcomes; Psoriasis; Systemic or biologic therapy.